Unraveling the Gut Microbiota: Key Insights into its Role in Gastrointestinal and Cardiovascular Health

Seema Charitha Cheemala [a], Saif Syed [b], Ruqiya Bibi [c], Muawaz Bin Suhail [c], Mayankkumar D Dhakecha [d], Muhammad Subhan [c,e*], Muhammad Shoaib Mahmood [f], Ahsan Shabbir [f], Hamza Islam [g] and Rabia Islam [g]

[a] *Rajiv Gandhi Institute of Medical Sciences, Adilabad, Telangana, India.*
[b] *RCSI Royal College of Surgeons in Ireland, Dublin, Ireland.*
[c] *Allama Iqbal Medical College, Lahore, Pakistan.*
[d] *Government Medical College, Surat, India.*
[e] *Jinnah Hospital Lahore, Pakistan.*
[f] *Akhtar Saeed Medical and Dental College, Lahore, Pakistan.*
[g] *Punjab Medical College, Faisalabad, Pakistan.*

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Minireview Article

_____

*Corresponding author: E-mail: muhammadsubhan1998@gmail.com;

ABSTRACT

The human gastrointestinal (GI) tract harbors a diverse and dynamic community of microorganisms known as the gut microbiome, which plays a fundamental role in maintaining gastrointestinal (GI) and cardiovascular health. It explores the intricate interplay between the gut microbiota, GI health, and cardiovascular diseases (CVDs). It discusses the essential roles of the gut microbiome in energy metabolism, nutrient absorption, immune regulation, and gut barrier integrity. Dysbiosis, characterized by an imbalance in gut microbiota composition, has been linked to various GI conditions, including inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), as well as CVDs such as hypertension, atherosclerosis, and heart failure. Therapeutic strategies targeting the gut microbiome, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and precision nutrition, offer promising avenues for managing GI and cardiovascular diseases. Recent research has brought attention to the significance of gut microbiota in CVDs, highlighting sex-specific variations, microbial metabolites' impact, and potential therapeutic interventions. Challenges in microbiome research, such as sample size limitations and methodological variability, are addressed, along with opportunities for innovation, including multi-omics integration and personalized medicine guided by microbiome data. By addressing these challenges and leveraging opportunities, gut microbiome research can revolutionize healthcare, ushering in a new era of personalized and microbiome-informed medicine. This comprehensive analysis offers valuable perspectives into the intricate relationship between gut microbiota, GI health, and cardiovascular diseases, paving the way for future research and clinical applications in this burgeoning field.

1. INTRODUCTION

The human gastrointestinal (GI) tract harbors a rich and constantly changing assembly of microorganisms called the gut microbiome [1]. This intricate ecosystem comprises bacteria, archaea, fungi, viruses, and other organisms that coexist with the host in a symbiotic relationship [2]. It is crucial in upholding the equilibrium between wellness and illness within the gastrointestinal system, exerting its influence through myriad physiological functions [2,3]. Among its essential roles, the gut microbiome harvests energy from food, contributes to nutrient absorption and energy metabolism [4], and acts as a formidable barrier against pathogens, protecting the host from invading harmful microorganisms [5]. Additionally, it regulates immune function, influencing the development and maintenance of the immune system within the GI tract [6], which is crucial for homeostasis and defense against pathogens [6]. Moreover, the gut microbiome actively modulates the integrity of the gastrointestinal mucosa, contributing to the digestive system's overall structural and functional well-being [7]. Despite its essential contributions to health, the composition and function of the gut microbiome are susceptible to various influencing factors [8], including genetics, diet, environmental exposures, age, and medication, all of which shape the intricate balance of microbial communities within the GI tract [9]. Changes in the gut microbiota, often termed dysbiosis, have been linked to various gastrointestinal conditions, including conditions such as inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and colorectal cancer [10]. The human gastrointestinal (GI) tract is a complex ecosystem where trillions of microorganisms, collectively known as the gut microbiota, coexist with the host in a symbiotic relationship [1]. This intricate community plays a pivotal role in maintaining the balance between health and disease within the GI system [1]. Emerging findings indicate that the gut microbiome plays a role in cardiovascular health through various physiological functions [2]. For instance, gut bacteria can produce metabolites from dietary components that affect the host's cardiovascular condition, such as branched-chain amino acid metabolites, tryptophan, and histidine, which are associated with insulin resistance and vascular disease [3]. Additionally, the gut microbiota can modulate blood pressure and inflammation, critical factors in cardiovascular health [4]. Moreover, the gut microbiota metabolizes bile acids and other compounds with systemic effects, including cardiovascular events. Dysbiosis, characterized by an imbalance in gut microbiota composition, has been associated with numerous cardiovascular diseases (CVDs), such as hypertension, myocardial infarction, and atherosclerosis [5]. The gut microbiota's role in

CVD is significant and is being explored as a potential target for therapeutic interventions [6]. This literature review explores the interplay between gut microbiota, GI health, and cardiovascular diseases. It examines how the microbiota influences these conditions, discusses therapeutic strategies targeting the microbiota, and considers the clinical implications of this interplay [7]. It synthesizes current knowledge, identifies gaps, and highlights the potential for future research and clinical applications of the gut microbiome in the context of GI and cardiovascular health [7].

2. DISCUSSION

The human gastrointestinal (GI) tract is a complex and dynamic ecosystem with diverse microbial life [1,2]. This review delves into the complex interactions between the host and its microbial guests, highlighting the importance of balance and diversity within this microscopic world [3,4]. The gut microbiome profoundly modulates metabolic and immune processes [6]. It comprises a rich tapestry of bacteria, viruses, fungi, and archaea, each contributing uniquely to the gut's function and overall well-being [7,8]. Bacteria, the most populous of these groups, are crucial for fermenting dietary fibers, producing beneficial short-chain fatty acids (SCFAs), and upholding the integrity of the gut barrier [7-9]. Bacteriophages, viruses that infect bacteria, are instrumental in sculpting bacterial populations and fostering microbial diversity [9]. Fungi, including yeasts and filamentous species, while less understood, are believed to contribute to the stability of the gut ecosystem [10]. Archaea, ancient organisms adept at surviving extreme conditions, are involved in methane metabolism and other significant metabolic pathways within the gut [11]. The symbiotic connection between the gut microbiome and the host is evident, with microbes aiding in breaking down complex carbohydrates and generating energy and vital nutrients, such as B vitamins [10-12]. A well-balanced microbiome is essential for maintaining the gut barrier, which acts as a selective gateway, barring harmful substances while permitting the passage of essential nutrients [12]. In cardiovascular health, recent studies suggest that the gut microbiome may also influence heart disease [5,6]. Dysbiosis has been associated with the development of atherosclerosis, hypertension, and heart failure [5,6]. The potential of modulating the gut microbiome through diet, probiotics, and prebiotics offers promising therapeutic strategies for both GI and cardiovascular diseases [5,6]. These interventions aim to restore microbial balance, reduce inflammation, and improve metabolic health, which could have far-reaching clinical implications [5,6]. Understanding the mechanisms behind these interactions is crucial for developing targeted therapies that harness the microbiome's potential to improve health outcomes [12-19]. Dysbiosis can dysregulate immune responses within the gut, leading to chronic low-grade inflammation and immune activation [19]. A shift in the gut microbiota configuration may release pro-inflammatory cytokines and chemokines, contributing to developing and exacerbating gastrointestinal diseases such as IBD and IBS [19]. It compromises the integrity of the gut barrier, resulting in heightened intestinal permeability and the migration of harmful substances (e.g., bacterial toxins, inflammatory chemicals), resulting in their movement from the intestinal lumen into the bloodstream [19]. This phenomenon, known as "leaky gut," triggers systemic inflammation and contributes to the pathogenesis of gastrointestinal diseases [19]. It alters the metabolic activity of the gut microbiota, leading to dysregulated fermentation of dietary components and impaired nutrient metabolism [18,19]. These metabolic disturbances can exacerbate gastrointestinal symptoms and contribute to the progression of gastrointestinal diseases [18,19]. It disrupts communication along the gut-brain axis, influencing neural, endocrine, and immune signaling pathways [17]. This dysregulation contributes to the development and exacerbation of functional gastrointestinal disorders like IBS, characterized by abnormal gut motility, visceral hypersensitivity, and dysregulated pain perception [17]. It produces altered microbial metabolites, such as SCFAs, bile acids, and neurotransmitters [18]. These metabolites modulate host physiology and immune function, and dysregulated production may contribute to gastrointestinal diseases through various mechanisms, including inflammation, oxidative stress, and altered gut motility [18]. By elucidating the intricate interplay between the gut microbiome and gastrointestinal diseases, researchers can identify novel therapeutic targets and interventions to restore microbial balance and mitigate the risk of disease progression [12-19]. Understanding the underlying mechanisms driving microbiome-disease interactions is essential for developing personalized strategies to modulate the gut microbiome and promote gastrointestinal health [12-19].

Therapeutic Strategies Targeting the Gut Microbiome: Therapeutic strategies targeting the gut microbiome have shown promise in promoting gastrointestinal health and may have implications for cardiovascular diseases. Probiotics, live microorganisms known for their health benefits, have been demonstrated to influence the composition and function of the gut microbiota, enhance barrier integrity, and regulate immune responses [20]. Clinical studies support their use in alleviating symptoms of gastrointestinal disorders such as diarrhea, IBS, and IBD [20]. Prebiotics, non-digestible fibers, stimulate the growth of beneficial bacteria and contribute to gut health by enhancing microbial diversity and SCFA production [21]. They have been shown to improve gastrointestinal symptoms and modulate immune function [22,23]. Fecal microbiota transplantation (FMT) has effectively treated recurrent Clostridium difficile infections and is being explored for other gastrointestinal diseases [24]. Emerging interventions include postbiotics, microbiota-targeted drugs, and precision nutrition [24-26]. Postbiotics, metabolites produced by probiotics, offer a stable and safe alternative for therapeutic intervention [25]. Microbiota-targeted drugs provide a precision medicine approach to restoring microbial balance [25]. Precision nutrition tailors dietary interventions to an individual's gut microbiome composition and metabolic profile, optimizing nutritional choices to promote beneficial microbes and mitigate dysbiosis-associated diseases [26]. To provide a comprehensive overview of the research landscape concerning gut microbiota and its implications for gastrointestinal health, we have compiled a summary of noteworthy studies in the field.

Table 1 highlights key findings, study designs, and publication years, offering valuable insights into the evolving understanding of gut microbiota's role in gastrointestinal disorders.

In cardiovascular health, these strategies may influence heart disease by modulating inflammatory responses, affecting blood pressure regulation, and impacting cholesterol metabolism [5,6]. The gut microbiome's role in producing metabolites like SCFAs and secondary bile acids suggests a link between gut health and cardiovascular diseases [5,6]. Therefore, therapeutic strategies targeting the gut microbiome could offer novel approaches to managing cardiovascular risk factors and improving patient outcomes [5,6]. Several studies shed light on the intricate relationship between gut microbiota and human health. Ley et al. compared gut microbiota in obese and lean individuals, finding reduced Bacteroidetes in obesity [27]. It showed diet's potential to reverse this, emphasizing microbiota's role in obesity and dietary interventions' impact on gut microbial communities [27]. In a randomized dietary intervention pilot trial involving 23 adults newly diagnosed with type 2 diabetes mellitus (T2DM), Michal Rein et al. investigated the effects of personalized diets based on a prediction of glycemic responses [28]. Subjects were assigned randomly to receive either a customized postprandial-targeting (PPT) diet or a Mediterranean-style (MED) diet in a crossover design. The PPT diet, guided by a machine learning algorithm predicting personal postprandial glucose responses (PPGR) and monitored using continuous glucose monitoring (CGM), yielded significant improvements compared to the MED diet [28]. These improvements included lower average PPGR, mean glucose, and the duration each day when glucose levels exceeded 140 mg/dl, as well as decreased blood fructosamine levels [28]. After a 6-month PPT intervention, further enhancements were observed in HbA1c, fasting glucose, and triglyceride levels. Notably, 61% of participants achieved diabetes remission with HbA1c <6.5% [28]. The study underscored the clinical efficacy of personalized dietary interventions in enhancing glycemic control and metabolic health among individuals with newly diagnosed T2DM [28]. It utilized a machine learning algorithm to predict personalized postprandial glucose responses (PPGR) based on clinical and microbiome features, highlighting the significance of gut microbiota in shaping individual glycemic responses to dietary intake [28]. By implementing a personalized postprandial-targeting (PPT) diet guided by these predictions, the study demonstrated significant improvements in glycemic control, metabolic health, and diabetes remission rates compared to a Mediterranean-style (MED) diet [28]. This underscores the crucial role of gut microbiota in modulating glycemic responses to dietary interventions and suggests the potential for microbiota-targeted strategies to enhance personalized nutrition and metabolic outcomes in individuals with T2DM [28]. This study advances tailored dietary interventions for improved efficacy and personalization [28]. Vandeputte et al. explored the relationship between gut microbiota diversity and stool consistency using the Bristol Stool Scale (BSS) [29]. BSS classifications reflected

fecal water content and transit time [29]. Results showed strong correlations between stool consistency and microbiome markers, including species richness and specific bacterial genera [29]. Enterotypes varied across BSS scores, with transit time influencing bacterial growth rates [29]. These findings underscore the significance of stool consistency assessment in gut microbiome studies [29]. In a pioneering study, Binxu Qiu et al. employed Mendelian randomization to reveal potential causal links between gut microbiota and prevalent gastrointestinal ailments [30]. Notably, they found that Genus Oxalobacter was associated with Crohn's disease with OR = 1.29, 95% CI: 1.13–1.48, p = 2.5×10^{-4} and Family Clostridiaceae1 with irritable bowel syndrome with OR = 0.9967, 95% CI: 0.9944–0.9991, p = 1.3×10^{-3} [30]. These insights provide critical guidance for targeted interventions, illuminating the intricate relationship between gut microbiota composition and gastrointestinal health [30].

Together, these studies underscore the significance of gut microbiota in human health and pave the way for personalized strategies in disease management. The studies by Michal Rein et al., Vandeputte et al., and Binxu Qiu et al. contribute to our understanding of the gut microbiota's role in gastrointestinal health and diseases [27-30]. They highlight the potential of using gut microbiota data to design personalized nutrition and therapeutic interventions [19]. These studies highlight the significance of considering the gut microbiome in the context of both gastrointestinal and cardiovascular health [19-21]. The gut microbiota, comprising trillions of microorganisms residing in our intestines, plays a multifaceted role in human health [18]. Beyond digestion, it influences immune function, produces essential metabolites, and interacts with the host [18].

Gut Microbiota and Cardiovascular Risk Factors: The gut microbiota's influence extends beyond gastrointestinal health, impacting cardiovascular risk factors and diseases [22]. Dysbiosis, marked by an imbalance in the gut microbiota population, is associated with hypertension, obesity, and diabetes Mellitus (DM), all of which contribute to increased risk for cardiovascular diseases (CVDs) [22]. Chronic inflammation, driven by dysbiotic microbiota, is a critical factor in the development of atherosclerosis [22]. Metabolites produced by microorganisms, including short-chain fatty acids (SCFAs), as well as trimethylamine-N-oxide (TMAO), have been implicated in vascular health and lipid metabolism [12,13,22]. SCFAs, known for their anti-inflammatory properties, promote gut barrier integrity and may reduce CVD risk [22]. Propionate, one of the SCFAs, regulates lipid metabolism and insulin sensitivity, further linking gut health to cardiovascular health [22].

Table 1. Recent studies on gut microbiota and its impact on health

Authors	Study Design	Year of Publication	Type of Study	Brief Results
Michal Rein et al. [28]	Randomized Dietary Intervention	2022	Pilot Trial	Enabled personalized dietary recommendations to lower post-meal glucose levels. Demonstrated potential of microbiota-based precision nutrition.
Vandeputte et al. [29]	Observational	2016	Observational	Stool consistency correlated with significant microbiome markers. Enterotypes are distinctly distributed over BSS scores, and transit time acts as a selective force on gut bacterial growth rates.
Qiu et al. [30]	Mendelian Randomization	2023	Mendelian Randomization	Sixty-two microbial taxa were identified as potentially linked to gastrointestinal diseases. Notably, the Genus Oxalobacter is associated with Crohn's disease (OR = 1.29), and the Family Clostridiaceae1 is linked to irritable bowel syndrome (OR = 0.9967).

Dietary interventions are crucial in modulating the gut microbiota for improved cardiovascular health [22]. The Mediterranean Diet, rich in fiber, polyphenols, and beneficial fats, supports a healthy gut microbiome and, by extension, cardiovascular health [22]. Reducing red meat intake may lower TMAO levels, potentially decreasing atherosclerosis risk [12,22]. Personalized dietary interventions targeting microbial metabolites and promoting gut health could complement traditional CVD therapies

[22,23]. Fig. 1 illustrates the interplay between diet, lifestyle factors, medication, and their impact on gut microbiota composition and its implications for gastrointestinal and cardiovascular health and diseases [22,23].

Recent studies have shed light on the gut microbiota's role in cardiovascular health and disease [23-27]. Some of the essential and latest studies with their brief findings are summarized in Table 2.


Fig. 1. interconnected influence: Gut microbiota in gastrointestinal and cardiovascular health

Table 2. Recent studies on the role of gut microbiota in gastrointestinal and cardiovascular health

Authors	Year of Publication	Brief Results
H. Garcia-Fernandez et al. [23]	2024	Evaluation of sex-specific variations in intestinal microbiota associated with cardiovascular diseases, suggesting sex-specific dysbiosis linked to coronary heart disease.
Murad Khan et al. [24]	2024	This section will focus on the gut microbiome's role in colorectal cancer treatment, discussing its influence on the development and regulation of the host immune system and its potential as a biomarker for immunotherapy efficacy.
L.Y. Zhao et al. [25]	2023	This reviews gut microbiota's role in anticancer therapy, summarizing molecular mechanisms, clinical applications, and the relationship between gut microbes and the efficacy of various cancer treatments.
S.K. Masenga et al. [26]	2022	The gut microbiota's influence on cardiovascular diseases, highlighting potential therapies for improving gut microbiota composition for better cardiovascular health.
L. Wang et al. [27]	2022	The involvement of gut microbiota in maintaining health and cardiovascular diseases emphasizes significant differences in composition and ratio between patients with CVDs and healthy individuals.

The latest research has brought significant insights into the correlation between the microorganisms residing in the gastrointestinal tract and diverse aspects of human health conditions, particularly cardiovascular diseases (CVDs) and cancer treatment [23-27]. In a study conducted by H. Garcia-Fernandez et al., the focus was on discerning sex-specific differences in intestinal microbiota associated with CVDs. Their analysis, involving a considerable cohort of individuals, revealed distinct variations in gut microbiota composition between men and women affected by coronary heart disease (CHD), shedding light on potential sex-specific biomarkers for CHD [23]. Similarly, Murad Khan et al. delved into the involvement of the gut microbiota in the treatment of colorectal cancer [24]. Their findings emphasized the microbiome's crucial involvement in shaping host immune responses during cancer therapy, hinting at its potential as a predictive biomarker for immunotherapy outcomes in colorectal cancer patients [24]. Expanding beyond cancer, L.Y. Zhao et al. explored the broader implications of the gut microbiota in anticancer therapy [25]. Their comprehensive review highlighted the intricate molecular mechanisms underlying microbiota-mediated responses to cancer treatment, paving the way for more targeted therapeutic interventions [25]. Meanwhile, S.K. Masenga et al. focused on the influence of gut microbiota on cardiovascular diseases [26]. Their study underscored the significant impact of microbiota composition on cardiovascular health, suggesting potential therapeutic strategies aimed at optimizing gut microbiota composition to improve cardiovascular outcomes [26]. Lastly, in a study by L. Wang et al., the emphasis was on the role of gut microbiota in maintaining health and its involvement in cardiovascular diseases [27]. By comparing gut microbiota composition between patients with CVDs and healthy individuals, they highlighted notable differences that could inform future therapeutic interventions targeting the gut microbiota to promote cardiovascular health [27]. Collectively, these studies depict valuable insights into the intricate dynamic between gut microbiota and the consequences for health, offering promising avenues for therapeutic interventions and diagnostic advancements in cardiovascular diseases and cancer treatment [23-27]. A study highlighted the potential of gut microbiota modulation by antibiotics or fecal microbiota transplantation (FMT) to enhance heart function and mitigate adverse remodeling after myocardial infarction [24]. These findings underscore the gut microbiota's significance in cardiovascular health and the potential for novel diagnostic and therapeutic strategies [23-30]. The gut microbiota, the population of living microbes in the human intestines, may mediate some risk factors affecting cardiovascular health [22,23]. For example, some bacteria can break down cholesterol, while others can produce compounds that regulate blood pressure [22,23]. Some of the latest original studies exploring microbiota's role in cardiovascular health and disease are briefly explained here [26]. Sachin Aryal et al. analyzed fecal 16S ribosomal RNA sequencing data from 478 CVD and 473 non-CVD human subjects collected through the American Gut Project [31]. The study identified 39 differential bacterial taxa between the CVD and non-CVD groups [31]. Machine learning models using these taxonomic features attained an area under the curve (AUC) of the receiver operating characteristic (ROC) curve of approximately 0.58 with random forest and neural networks [31]. Using the top 500 high-variance features of operational taxonomic units instead of bacterial taxa, the AUC improved to approximately 0.65 with random forest [31]. Further enhancement to an AUC of approximately 0.70 was achieved by limiting the selection to only the top 25 highly contributing operational taxonomic unit features [31]. This study is the first to apply machine learning to gut microbiota data for diagnostic screening of cardiovascular disease [31]. The article by Xue et al. explores the intricate microecosystem comprising the gut microbiota, metabolome, and host immunome and its significant role in cancer pathogenesis and therapy [32]. They discuss how the gut microbiota is not merely a passive entity but an active participant in various biological activities, including response and metabolism [32]. The study emphasizes the interaction between the host and microbiota, which profoundly influences the development of the immune system and its functions [32]. Pathologically, the gut microbiota can affect diversity and the layout, directly contributing to disease development [32]. The study suggests that despite current gut symbiotic microorganisms' low virulence, a pathogenicity surge can occur under certain conditions, leading to increased disease risk [32]. Etiologically, they highlight the nature of interactions between gut microbiota and cancer [32]. While the exact mechanisms remain elusive, the intestinal microbiota's role in tumor occurrence, progression, and treatment response is critical [32-34]. This underscores the potential of

targeting the microbiota in medicine and immunotherapy [32]. In summary, the study posits that understanding the micro-ecosystem is fundamental for analyzing pathogenesis and developing therapeutic strategies for cancer, pointing towards a future where gut microbiota modulation could become a cornerstone of effective cancer treatment [32]. Rahman et al. explored the link between gut microbiota and cardiovascular diseases (CVDs), investigating microbial metabolites' role [33]. Their findings highlighted how gut microbiota-derived compounds like trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), and bile salts influence CVD development [33]. These metabolites contribute to various cardiovascular conditions, including heart failure, atherosclerosis, hypertension, myocardial fibrosis, myocardial infarction, and coronary artery disease [33]. This study underscores the potential of therapeutic interventions targeting the microbiota for managing CVDs [33]. A study by Lijun Shang et al. investigated gut microbiota modulation by antibiotics or FMT on cardiac function and remodeling in a mouse myocardial infarction (MI) model [34-39]. The results showed that antibiotics and FMT improved cardiac function and reduced adverse remodeling after MI [34]. These effects were mediated by changes in the gut microbiota composition and metabolites, such as SCFAs and TMAO [34]. Hai-Jian Sun et al. conducted a study investigating the function of hydrogen sulfide (H2S) in facilitating cardioprotection through Nrf2 signaling [35]. The researchers found that H2S exerts cardioprotective effects by activating the Nrf2 signaling pathway [38-42]. This activation leads to increased expression of antioxidant enzymes and proteins implicated in cellular defense mechanisms, ultimately protecting cardiac tissues from oxidative stress and ischemic injury [35]. The study provides important insights into the molecular mechanisms underlying the cardioprotective effects of H2S and highlights its potential therapeutic implications for cardiovascular diseases [35-39]. The researchers found that gut microbiota produces H2S from dietary sulfur-containing amino acids [35]. This H2S acts as a vasodilator and anti-inflammatory agent, protecting against hypertension and vascular dysfunction [35]. The results suggest that dietary methionine restriction, which reduces sulfur-containing amino acids, may confer protective effects against hypertension and vascular dysfunction through the gut microbiota-derived H2S pathway [35]. A study by Eun Sil Kim in

February 2022 in Cell Metabolism examined the effects of gut microbiota manipulation by antibiotics, probiotics, or FMT on the development and advancement of atherosclerosis in a murine model [36]. The results demonstrated that different gut microbiota modulations had distinct impacts on atherosclerosis and were mediated by changes in the gut microbiota composition, metabolites, and immune responses [36]. These studies conclude that gut microbiota has a significant role in maintaining cardiovascular health and developing CVDs [31-36]. Modulating the gut microbiota may offer novel opportunities for diagnosing, preventing, and treating CVDs [43-45]. However, more research is needed to elucidate the causal mechanisms and pathways linking the gut microbiota to CVDs and to translate the findings from animal models to human clinical settings [46,47].

Challenges, Opportunities, and Implications in Gut Microbiome Research and Practice: Microbiome research faces numerous challenges, including limitations in sample size, methodological variability, and difficulties in establishing causality [26,47]. Small sample sizes and limited diversity in study populations hinder the generalizability of findings [47,48]. Methodological variability in sample collection, processing techniques, and analytical methods can introduce inconsistencies and biases, impacting the reproducibility of results [47-49]. Moreover, establishing causality in microbiome-disease relationships remains challenging, as many associations identified may be correlative rather than causative [47]. Ethical concerns surround FMT, necessitating rigorous safety assessments and ethical oversight [47]. Despite these challenges, microbiome research presents exciting opportunities for innovation [48]. Integration of multi-omics data, utilization of machine learning, and microbiome engineering offer novel approaches to understanding and manipulating microbial communities [48]. Personalized medicine guided by microbiome data holds promise for tailored interventions, optimizing clinical outcomes, and minimizing adverse effects [49]. Integrating microbiome insights into clinical practice can enhance precision medicine and public health initiatives, promoting gastrointestinal health and mitigating associated disorders [48-50]. Regulatory frameworks are vital for ensuring microbiome-based interventions' safe and ethical use [48-53]. By addressing these challenges and seizing opportunities, gut microbiome research can

revolutionize healthcare and disease management, ushering in a new era of personalized and microbiome-informed medicine.

3. CONCLUSION

The gut microbiota, a complex and dynamic ecosystem within the human gastrointestinal tract, plays a pivotal role in maintaining gastrointestinal (GI) and cardiovascular health. This review has highlighted the multifaceted functions of the gut microbiome, including energy metabolism, nutrient absorption, immune regulation, and maintaining gut barrier integrity. Dysbiosis, an imbalance in gut microbiota composition, is linked to various GI conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), as well as cardiovascular diseases (CVDs) like hypertension, atherosclerosis, and heart failure. Therapeutic strategies targeting the gut microbiome, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and precision nutrition, show promising potential in managing GI and cardiovascular diseases. These interventions aim to restore microbial balance, reduce inflammation, and improve metabolic health, which could lead to significant clinical benefits. Recent research underscores the gut microbiota's considerable role in CVDs, revealing sex-specific variations and the impact of microbial metabolites on cardiovascular health. Despite advancements, challenges such as sample size limitations and methodological variability remain in microbiome research. Addressing these challenges through multi-omics integration and personalized medicine approaches could revolutionize healthcare. By leveraging these opportunities, gut microbiome research can pave the way for personalized and microbiome-informed medicine, potentially transforming the management and treatment of GI and cardiovascular diseases. Understanding the intricate relationship between gut microbiota, GI health, and cardiovascular diseases provides valuable insights and a foundation for future research and clinical applications. As our knowledge of the gut microbiome's role in health and disease deepens, innovative therapeutic strategies can be developed, offering hope for improved outcomes in GI and cardiovascular health.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

The author(s) hereby declare that generative AI technologies, such as Large Language Models (LLMs), have been employed in the writing and editing of this manuscript. The AI tools were used specifically for fine-tuning the reprocessing of the article to remove grammatical errors and to proofread the content after the original manuscript was prepared through extensive database searches and writing efforts. The following details provide a comprehensive overview of the AI usage:

Generative AI Technology Details:

- Name: ChatGPT
- Version: GPT-4
- Model: GPT-4 (Large Language Model by OpenAI)
- Source: OpenAI

Input Prompts Provided to the Generative AI Technology:

1. Grammar Check and Correction:

   - Prompt: "Please proofread the following text for grammatical errors and provide corrections: [insert text]."
   - Example: "Please proofread the following text for grammatical errors and provide corrections: The study aims to investigate the impact of AI on healthcare systems. It is crucial to analyze both the positive and negative effects."

2. Proofreading and Clarity Enhancement:

   - Prompt: "Enhance the clarity and readability of the following text while maintaining the original meaning: [insert text]."
   - Example: "Enhance the clarity and readability of the following text while maintaining the original meaning: This paper explores the various applications of AI in modern medicine, including diagnostics, treatment planning, and patient monitoring."

3. Stylistic Adjustments:

   - Prompt: "Refine the following passage to improve its academic tone and consistency: [insert text]."
   - Example: "Refine the following passage to improve its academic tone and consistency: With the advent of advanced AI technologies, the

healthcare industry has seen significant transformations. These innovations have streamlined processes and enhanced patient outcomes."

Additional Notes:

- The AI tool was used strictly for editorial assistance and did not contribute to the substantive content or research findings of the manuscript.
- The final responsibility for the content, including any errors or omissions, rests with the author(s).

By providing these details, the author(s) ensure transparency regarding the use of AI technologies in the manuscript preparation process.

CONSENT

It is not applicable.

ETHICAL APPROVAL

The authors confirm that appropriate ethical considerations were followed during this study. The study is not submitted or under publication in any journal.

ACKNOWLEDGEMENTS

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Sender R, Fuchs S, Milo R. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. Cell. 2016;164(3):337-340.
2. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823-1836.
3. 3.Sonnenburg JL, Sonnenburg ED. Vulnerability of the industrialized microbiota. Science. 2019 Oct 25; 366(6464):eaaw9255. doi:10.1126/science.aaw9255. PMID: 31649168.
4. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-141.
5. Boutagy NE, McMillan RP, Frisard MI, Hulver MW. Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie. 2016 May;124:11-20. DOI:10.1016/j.biochi.2015.06.020. Epub 2015 Jun 29. PMID: 26133659; PMCID: PMC4695328.
6. Spencer CN, McQuade JL, Gopalakrishnan V, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24;374(6575):1632-1640. DOI: 10.1126/science.aaz7015. Epub 2021 Dec 23. PMID: 34941392; PMCID: PMC8970537.
7. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65(2):330-339.
8. Tan J, Taitz J, Nanan R, Grau G, Macia L. Dysbiotic Gut Microbiota-Derived Metabolites and Their Role in Non-Communicable Diseases. Int J Mol Sci. 2023 Oct 17;24(20):15256. DOI: 10.3390/ijms242015256. PMID: 37894934; PMCID: PMC10607102.
9. Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8(1):845.

10. Volodina DE, Gureev AP, Shaforostova EA, Gryaznova MV, Ignatyeva DA, Popov VN. Effect of l-carnitine and mildronate on the mitochondrial metabolism of heart and bacterial composition of the gut microbiome in ageing mice. Life Sci. 2022 Mar 15;293:120333.
DOI:10.1016/j.lfs.2022.120333. Epub 2022 Jan 18. PMID: 35051422.

11. Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124(10):4204-4211.

12. Ma J, Li H. The role of gut microbiota in atherosclerosis and hypertension. Front Pharmacol. 2018;9:1082.

13. Belli M, Barone L, Longo S, Prandi FR, Lecis D, Mollace R, Margonato D, Muscoli S, Sergi D, Federici M, et al. Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target? International Journal of Molecular Sciences. 2023;24(15):11971. Available:https://doi.org/10.3390/ijms241511971

14. Emoto T, Yamashita T, Sasaki N, Hirota Y, Hayashi T, So A, et al. Analysis of gut microbiota in coronary artery disease patients: a possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb. 2016;23(8):908-921.

15. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111-124.

16. Koopen AM, Groen AK, Nieuwdorp M. Human microbiome as therapeutic intervention target to reduce cardiovascular disease risk. Biochim Biophys Acta Mol Basis Dis. 2019;1865(7): 981-984.

17. Jonsson AL, Bäckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017;14(2):79-87.

18. 18.Clapp M, Aurora N, Herrera L, Bhatia M, Wilen E, Wakefield S. Gut microbiota's effect on mental health: The gut-brain axis. Clin Pract. 2017 Sep 15;7(4):987.
DOI: 10.4081/cp.2017.987. PMID: 29071061; PMCID: PMC5641835.

19. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018 Jun 13;361:k2179.
DOI:10.1136/bmj.k2179.
PMID: 29899036; PMCID: PMC6000740.

20. Vandeputte D, Kathagen G, D'hoe K, Vieira-Silva S, Valles-Colomer M, Sabino J, Wang J, Tito RY, De Commer L, Darzi Y, Vermeire S, Falony G, Raes J. Quantitative microbiome profiling links gut community variation to microbial load. Nature. 2017 Nov 23;551(7681):507-511.
DOI:10.1038/nature24460. Epub 2017 Nov 15.
PMID: 29143816.

21. Zhao T, Wang X, Fu L, Yang K. Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response. Cancer Drug Resist. 2022 May 12;5(2):436-450.
DOI:10.20517/cdr.2021.144.
PMID: 35800370; PMCID: PMC9255244.

22. Wang L, Wang S, Zhang Q, He C, Fu C, Wei Q. The role of the gut microbiota in health and cardiovascular diseases. Mol Biomed. 2022 Oct 11;3(1):30.
DOI: 10.1186/s43556-022-00091-2.
PMID: 36219347; PMCID: PMC9554112.

23. Garcia-Fernandez H, Arenas-de Larriva AP, Lopez-Moreno J, Gutierrez-Mariscal FM, Romero-Cabrera JL, Molina-Abril H, Torres-Peña JD, Rodriguez-Cano D, Malagon MM, Ordovas JM, Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Camargo A. Sex-specific differences in intestinal microbiota associated with cardiovascular diseases. Biol Sex Differ. 2024 Jan 19;15(1):7.
DOI: 10.1186/s13293-024-00582-7. PMID: 38243297; PMCID: PMC10797902.

24. Khan M, Shah S, Shah W, Khan I, Ali H, Ali I, Ullah R, Wang X, Mehmood A, Wang Y. Gut microbiome as a treatment in colorectal cancer. Int Rev Immunol. 2024 Feb 12:1-19.
DOI:10.1080/08830185.2024.2312294.
Epub ahead of print. PMID: 38343353.

25. Ji M, Xu X, Xu Q, Hsiao YC, Martin C, Ukraintseva S, Popov V, Arbeev KG, Randall TA, Wu X, Garcia-Peterson LM, Liu J, Xu X, Andrea Azcarate-Peril M, Wan Y, Yashin AI, Anantharaman K, Lu K, Li JL, Shats I, Li X. Methionine restriction-induced sulfur deficiency impairs antitumour immunity partially through gut microbiota. Nat Metab. 2023 Sep;5(9): 1526-1543.
DOI: 10.1038/s42255-023-00854-3. Epub 2023 Aug 3.
PMID: 37537369; PMCID: PMC10513933.

26. Zhao LY, Mei JX, Yu G, Lei L, Zhang WH, Liu K, Chen XL, Kołat D, Yang K, Hu

JK. Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. Signal Transduct Target Ther. 2023 May 13;8(1):201.
DOI: 10.1038/s41392-023-01406-7.
PMID: 37179402; PMCID: PMC10183032.

27. Masenga SK, Hamooya B, Hangoma J, Hayumbu V, Ertuglu LA, Ishimwe J, Rahman S, Saleem M, Laffer CL, Elijovich F, Kirabo A. Recent advances in modulation of cardiovascular diseases by the gut microbiota. J Hum Hypertens. 2022 Nov;36(11):952-959.
DOI: 10.1038/s41371-022-00698-6. Epub 2022 Apr 25.
PMID: 35469059; PMCID: PMC9649420.

28. Rein M, Ben-Yacov O, Godneva A. et al. Effects of personalized diets by predicting glycemic responses on glycemic control and metabolic health in newly diagnosed T2DM: a randomized dietary intervention pilot trial. BMC Med. 2022;20:56.
Available: https://doi.org/10.1186/s12916-022-02254-y

29. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016 Jan;65(1):57-62.
DOI: 10.1136/gutjnl-2015-309618. Epub 2015 Jun 11.
PMID: 26069274; PMCID: PMC4717365.

30. Qiu B, Shen Z, Yang D, Qin X, Ren W, Wang Q. Gut microbiota and common gastrointestinal diseases: a bidirectional two-sample Mendelian randomized study. Front Microbiol. 2023 Nov 17;14:1273269.
doi: 10.3389/fmicb.2023.1273269. PMID: 38045030; PMCID: PMC10691374.

31. Aryal S, Alimadadi A, Manandhar I, Joe B, Cheng X. Machine Learning Strategy for Gut Microbiome-Based Diagnostic Screening of Cardiovascular Disease. Hypertension (Dallas, Tex. :1979). 2020 Nov;76(5):1555-1562.
DOI: 10.1161/hypertensionaha.120.15885.
PMID: 32909848; PMCID: PMC7577586.

32. Xue X, Li R, Chen Z, Li G, Liu B, Guo S, Yue Q, Yang S, Xie L, Zhang Y, Zhao J, Tan R. The role of the symbiotic micro-ecosystem in cancer: gut microbiota, metabolome, and host immunome. Front Immunol. 2023 Aug 24;14:1235827.
DOI: 10.3389/fimmu.2023.1235827. PMID: 37691931; PMCID: PMC10484231

33. Rahman MM, Islam F, -Or-Rashid MH, Mamun AA, Rahaman MS, Islam MM, Meem AFK, Sutradhar PR, Mitra S, Mimi AA, Emran TB, Fatimawali, Idroes R, Tallei TE, Ahmed M, Cavalu S. The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation. Front Cell Infect Microbiol. 2022 Jun 20;12:903570.
DOI: 10.3389/fcimb.2022.903570. PMID: 35795187; PMCID: PMC9251340.

34. Shang L, Tu J, Dai Z, Zeng X, Qiao S. Microbiota Transplantation in an Antibiotic-Induced Bacterial Depletion Mouse Model: Reproducible Establishment, Analysis, and Application. Microorganisms. 2022 Apr 26;10(5):902.
DOI: 10.3390/microorganisms10050902. PMID: 35630347; PMCID: PMC9146686.

35. Sun HJ, Wu ZY, Nie XW, Wang XY, Bian JS. An Updated Insight Into Molecular Mechanism of Hydrogen Sulfide in Cardiomyopathy and Myocardial Ischemia/Reperfusion Injury Under Diabetes. Frontiers in Pharmacology. 2021;12:651884.
DOI: 10.3389/fphar.2021.651884.
PMID: 34764865; PMCID: PMC8576408.

36. Kim ES, Yoon BH, Lee SM, Choi M, Kim EH, Lee BW, Kim SY, Pack CG, Sung YH, Baek IJ, Jung CH, Kim TB, Jeong JY, Ha CH. Fecal microbiota transplantation ameliorates atherosclerosis in mice with C1q/TNF-related protein 9 genetic deficiency. Exp Mol Med. 2022 Feb;54(2):103-114.
DOI:10.1038/s12276-022-00728-w. Epub 2022 Feb 3.
PMID: 35115674; PMCID: PMC8894390.

37. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nature reviews Gastroenterology & hepatology. 2012 Oct;9(10):599-608.

38. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy DN. Role of the normal gut microbiota. World journal of gastroenterology: WJG. 2015 Aug 8;21(29):8787.

39. Góralczyk-Bińkowska A, Szmajda-Krygier D, Kozłowska E. The Microbiota-Gut-Brain Axis in Psychiatric Disorders. Int J Mol Sci. 2022 Sep 24;23(19):11245.
DOI: 10.3390/ijms231911245. PMID: 36232548; PMCID: PMC9570195.

40. Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019 Feb;76(3):473-493. doi:

10.1007/s00018-018-2943-4. Epub 2018 Oct 13. PMID: 30317530; PMCID: PMC11105460.

41. Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019 Dec;20(4):461-472.
DOI: 10.1007/s11154-019-09512-0.
PMID: 31707624; PMCID: PMC6938793.

42. 42. Ling Z, Liu X, Cheng Y, Yan X, Wu S. Gut microbiota and aging. Crit Rev Food Sci Nutr. 2022;62(13):3509-3534.
DOI:10.1080/10408398.2020.1867054.
Epub 2020 Dec 30. PMID: 33377391.

43. Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The Gut Microbiota in Inflammatory Bowel Disease. Front Cell Infect Microbiol. 2022 Feb 22;12:733992.
DOI:10.3389/fcimb.2022.733992.
PMID: 35273921; PMCID: PMC8902753.

44. Asadi A, Shadab Mehr N, Mohamadi MH, Shokri F, Heidary M, Sadeghifard N, Khoshnood S. Obesity and gut-microbiota-brain axis: A narrative review. J Clin Lab Anal. 2022 May;36(5):e24420.
DOI: 10.1002/jcla.24420. Epub 2022 Apr 14.
PMID: 35421277; PMCID: PMC9102524.

45. Wang J, Zhu N, Su X, Gao Y, Yang R. Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis. Cells. 2023 Mar 2;12(5):793.
DOI: 10.3390/cells12050793. PMID: 36899929; PMCID: PMC10000530.

46. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018 Feb;11(1):1-10.
DOI: 10.1007/s12328-017-0813-5. Epub 2017 Dec 29. PMID: 29285689.

47. Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front Endocrinol (Lausanne). 2020 Jan 31;11:25.
DOI: 10.3389/fendo.2020.00025.
PMID: 32082260; PMCID: PMC7005631.

48. Maynard C, Weinkove D. The Gut Microbiota and Ageing. Subcell Biochem. 2018;90:351-371.
DOI: 10.1007/978-981-13-2835-0_12.
PMID: 30779015.

49. Chen L, Wang J. Gut microbiota and inflammatory bowel disease. WIREs Mech Dis. 2022 Mar;14(2):e1540.
DOI: 10.1002/wsbm.1540. Epub 2021 Oct 15. PMID: 35266651.

50. Illiano P, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease. FEBS J. 2020 Mar;287(5):833-855.
DOI: 10.1111/febs.15217. Epub 2020 Feb 3. PMID: 31955527.

51. Ibrahim Ali Babekir R, Mergani A, Mohamed Elshiekh MY, Mohamed Nour BY. Prevalence of Some Diarrhea Pathogens among under 5, in Wad Medani Pediatric Teaching Hospital, Gezira State, Sudan. Int. J. Trop. Dis. Health. [Internet]. 2023 Feb. 13 [cited 2024 May 28];44(2):49-57.
Available:https://journalijtdh.com/index.php/IJTDH/article/view/1389

52. Elmisbah HOII, Alonezy AAM, Alanazi STA, Alanazi SNA. Intestinal Obstruction Etiology, Diagnosis and Management. J. Pharm. Res. Int. [Internet]. 2022 Mar. 12 [cited 2024 May 28];34(23A):33-41.
Available:https://journaljpri.com/index.php/JPRI/article/view/6103

53. Kim Y, Pritts TA. The gastrointestinal tract. Geriatric trauma and critical care. 2017:35-43. critical care. 2017:35-43.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/118211